Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
118 Results for "
MAP3K
" in MedChemExpress (MCE) Product Catalog:
Products (118)
118 Results for "MAP3K" in MCE Product Catalog:
3
3 Cited Publications
Cat. No.: HY-32018
CAS No.: 915363-56-3
Cot inhibitor-2 is a potent, selective and orally active cot (Tpl2/MAP3K8) inhibitor with an IC50 of 1.6 nM. Cot inhibitor-2 inhibts TNF-α production in LPS-stimulated human whole blood with an IC50 of 0.3 μM .
2
2 Cited Publications
Target:
Research Areas:
Tpl2 Kinase Inhibitor 1 is a 3-pyridylmethylamino analog, and is a selective Tpl2 inhibitor (IC50=50 nM). Tpl2 consists of COT kinase and MAP3K8. Tpl2 Kinase Inhibitor 1 plays an important role in the regulation of the inflammatory response and the progression of some cancers .
1
1
1
1
1
1
1 Cited Publications
Cat. No.: HY-P703591
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: MAP3K7; TGF-Beta Activated Kinase 1; Prev. TAK1; TGF1a; MEKK7; CSCF; Transforming Growth Factor-Beta-Activated Kinase 1; FMD2; Mitogen-Activated Protein Kinase Kinase Kinase 7; TGF-Beta-Activated Kinase 1; TAB1; TGF-Beta-Activated Kinase 1-Binding Protein
Species:
Human
Source:
Sf9 insect cells
7,3',4'-Trihydroxyisoflavone, a major metabolite of Daidzein, is an ATP-competitive inhibitor of Cot (Tpl2/MAP3K8) and MKK4. 7,3',4'-Trihydroxyisoflavone has anticancer, anti-angiogenic, chemoprotective, and free radical scavenging activities .
Research Areas:
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines [3].
Target:
Research Areas:
SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC50 and EC50 values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC50 and EC50 values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (Kd=3.5 μM) than ENL YEATS (Kd=30 nM). SR-0813 can be used for the research of acute leukemia .
Target:
Research Areas:
DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research .
Cat. No.: HY-175809
Target:
Research Areas:
SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44 + breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, ERBB2, ERBB4, MAP3K10 and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer .
Cat. No.: HY-170595
CAS No.: 2763268-64-8
PROTAC LZK degrader 1 is an LZK (MAP3K13) PROTAC degrader. PROTAC LZK degrader 1 binds LZK with a Kd of 35 nM and recruits VHL E3 ubiquitin ligase to induce ubiquitin-proteasome dependent degradation of LZK in MAP3K13-amplified HNSCC cells. PROTAC LZK degrader 1 eliminates both kinase-dependent c-MYC stabilization and kinase-independent GOF p53 accumulation downstream of LZK, suppresses colony formation of LZK-amplified head and neck squamous cell carcinoma (HNSCC) cells. PROTAC LZK degrader 1 can be used for research on LZK-driven HNSCC .
Cat. No.: HY-RS08046
Target:
Research Areas:
MAP3K1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08047
Target:
Research Areas:
MAP3K10 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08048
Target:
Research Areas:
MAP3K11 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08049
Target:
Research Areas:
MAP3K12 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08050
Target:
Research Areas:
MAP3K13 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08051
Target:
Research Areas:
MAP3K14 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
